- Retrospective single-arm cohort of 31 patients (35 knees), mean age 73.6 years, with Kellgren-Lawrence grade 3 or 4 in 91%, treated at a single setting.
- Patients received ultrasound-guided cooled radiofrequency ablation for knee osteoarthritis, with outcomes compared from baseline to 3 months; no control group was included.
- Walking VAS pain fell by 24.0 points and KOOS Pain rose by 12.8 points (p < 0.001), with 42.9% of knees reaching at least a 50% walking-pain reduction.
- The authors concluded that pain and function improved at 3 months without group-level worsening of KL grade, alignment, or bone marrow lesions, and that no serious procedure-related adverse events were recorded.
Latest papers
Results for “genicular radiofrequency”.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- This is a narrative discourse rather than a trial, reviewing debates on radiofrequency ablation of the genicular nerves for chronic knee osteoarthritis pain.
- It addresses six controversies: prognostic blocks, final cannula placement, which nerves to target, ultrasound versus fluoroscopy, pulsed radiofrequency, and use after knee arthroplasty.
- The abstract notes earlier studies reporting pain relief lasting up to 12 months, while recent randomized trials have questioned RFA efficacy.
- The authors attribute conflicting results partly to heterogeneity in patient selection and technical protocols, and aim to guide clinicians and prompt further research.
- Cadaveric study of ten native and ten prosthetic knee capsules, sampling five genicular nerve target regions with histologic and immunohistochemical analysis.
- Compared intracapsular nerve ending and vascular densities between native and prosthetic knees; no clinical treatment was tested.
- Native knees had higher free nerve ending density (p < 0.001), while prosthetic knees had greater vascular density (p = 0.001) and more Pacini, Golgi and unclassified endings.
- FNE-vascular correlation was modest in native knees (r = 0.41) and negligible in prosthetic knees (r = 0.09); the authors suggest dense FNEs support nerve-targeted OA pain treatment.
- This systematic review pooled prospective randomized trials and observational studies of preoperative genicular nerve radiofrequency ablation before total knee arthroplasty.
- The comparison was ablation against control procedures, assessing function, pain, opioid use, length of stay, and complications.
- Trials showed no meaningful improvement in medium- to long-term function, acute pain, or length of stay, and no clear rise in complications was found.
- Retrospective data hinted at fewer long-term opioid refills, but no study stratified outcomes by baseline risk, so high-risk patients remain untested.
- Retrospective single-center cohort of 1,025 consecutive knees with symptomatic knee osteoarthritis treated between June 2024 and June 2026.
- All knees received ultrasound-guided cooled radiofrequency ablation using the MDNT technique, which adds physiological confirmation before ablation; there was no comparator group.
- Mean NRS pain fell from 7.76 to 2.46 by postoperative day 1 (mean reduction 5.29; 95% CI 5.16-5.43; P < 0.001) among 1,021 knees with early data.
- Repeat CRFA occurred in 8 of 1,025 knees (0.8%), and repeat-CRFA-free survival was 99.8% at 12 months; the authors call the findings hypothesis-generating.
- A retrospective chart review of 31 patients who received 38 conventional genicular nerve RFAs at an academic medical center from 2016 to 2023.
- Conventional radiofrequency ablation of three genicular nerves using two-tined electrodes, in patients with a prior positive genicular nerve block; no comparator group was reported.
- Mean NRS reduction was -3.17 at 0-3 months, -1.31 at 3-6 months, and -1.92 at 6-12 months, and half of patients kept an MCID-level reduction for 11.17 months (95% CI: 7.29, 13.40).
- PROMIS Physical Health, PROMIS Mental Health, and PHQ-9 showed no statistically significant change, and a history of depression was associated with treatment failure.
- Retrospective observational comparative-effectiveness cohort of 90 patients with moderate-to-severe knee osteoarthritis, followed for 24 months.
- Compared cooled genicular radiofrequency ablation alone (n=50) with the same ablation plus intra-articular botulinum toxin type A (n=40), with a planned repeat BoNT-A injection at about 12 months in the combination group.
- Significant treatment-by-time interactions were found for NRS (ß=-0.84, 95% CI -1.21 to -0.47; P=0.0002) and WOMAC (ß=-6.3, 95% CI -9.4 to -3.2; P=0.0003).
- At 24 months, responder rates were 86.5% with combination therapy versus 51.1% with ablation alone (P=0.0004); the authors call for randomized trials to confirm this.
- This narrative practical review synthesizes indirect pharmacological and adjacent procedural evidence, with no dedicated comparative trial of local anesthetics within RFA.
- It suggests lidocaine 1% as a default for skin and track anesthesia, and avoiding lidocaine 2% near the target nerve where stimulation testing is done, based on mechanistic reasoning.
- Across five randomized trials outside interventional pain settings, premixing lidocaine and bupivacaine showed no onset advantage over bupivacaine alone and sometimes shortened duration.
- The authors conclude these considerations are provisional and call for prospective studies, and they provide an allergy substitution pathway centered on formal allergist evaluation.
- This health-policy analysis compares September 2025 draft Medicare LCDs for peripheral nerve injections in chronic pain with the final policies, and examines their equity implications.
- The draft policies would have limited coverage mainly to trigeminal neuralgia radiofrequency and certain corticosteroid injections, with lifetime caps; the final policies restored criteria-based coverage for several blocks.
- Four contractors published materially identical final LCDs, effective October 25, 2026, while participation in the collaborative process was reported separately from final publication.
- Pudendal, intercostal, ganglion impar, ulnar, and other peripheral-nerve procedures remain noncovered for chronic pain, and the authors highlight access implications of geographically discordant coverage.
- Pre-post study of 22 patients with knee osteoarthritis, assessed before treatment, at 3 weeks, and at 3 months.
- Patients received genicular nerve radiofrequency ablation, and the abstract describes no separate control group.
- Lift-up index and movement time improved significantly in both legs at 3 weeks and 3 months, while pain fell from 8.09 to 2.41 at 3 weeks and 4.18 at 3 months (p<0.0001).
- The authors conclude GNRFA contributes positively to postural stability; WOMAC function also improved, from 58.69 to 23.05 at 3 weeks and 36.15 at 3 months (p<0.001).
- Retrospective cohort of 44 patients with advanced knee osteoarthritis and chronic knee pain unresponsive to at least 3 months of conservative care.
- Ultrasound-guided radiofrequency ablation of three genicular nerves, with NRS and WOMAC scores assessed at baseline and at 1, 6, and 12 months; no comparator group was reported.
- NRS and WOMAC scores fell significantly at all follow-ups (p<0.001); clinical success (≥50% pain reduction) was 81.8% at 1 month, 75.0% at 6 months, and 11.4% at 12 months.
- Authors conclude benefit was greatest within 6 months, suggesting GNRFA is a medium-term option rather than a permanent one; no serious adverse events were reported.
- Prospective single-arm pilot trial in consecutive patients with chronic postsurgical pain after total knee arthroplasty; 5 of 15 screened patients completed the study.
- Patients received cooled radiofrequency ablation (Coolief system), with change in NRS pain score from baseline to 6 months as the primary endpoint.
- The NRS change did not reach statistical significance at 6 months, though responder analysis showed a substantial proportion with clinically meaningful improvement; the KSS trend was also nonsignificant.
- No adverse events were reported, and the authors conclude the approach appears safe and potentially effective, with larger studies needed.
- Prospective quasi-randomized controlled trial of 109 patients with persistent pain after knee arthroplasty, assigned by procedure group to genicular nerve treatment.
- Compared conventional radiofrequency thermocoagulation (RFT) with chemical neurolysis using phenol of the genicular nerves.
- Phenol had lower NRS at 1 month (3.67 vs 4.09, p=0.015) and 6 months (5.02 vs 6.52, p<0.001); 6-month ≥50% improvement was 43.6% vs 18.5% (p=0.005).
- Authors conclude both treatments are effective for persistent post-arthroplasty pain, complications were similar (5.5% vs 3.7%), and phenol's short-term benefit needs long-term confirmation.
- This PRISMA systematic review pooled 19 studies, including sham-controlled trials, active-comparator trials and cohorts, of genicular nerve block and radiofrequency ablation for knee osteoarthritis.
- Pooled random-effects meta-analysis was used where data were homogeneous, and structured narrative synthesis otherwise.
- RFA was associated with larger and more durable pain relief than GNB, often lasting 6-12 months, though most of the comparison evidence is indirect.
- Both approaches reduced pain with no serious procedure-related adverse events reported, and the authors call for head-to-head trials with standardised protocols and longer follow-up.